

THE LANCET

Haematology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Leentjens J, van Haaps TF, Wessels PF, Schutgens REG, Middeldorp S.
COVID-19-associated coagulopathy and antithrombotic agents—lessons after
1 year. *Lancet Haematol* 2021; published online April 27. [https://doi.org/10.1016/S2352-3026\(21\)00105-8](https://doi.org/10.1016/S2352-3026(21)00105-8).

Supplementary Table 1. Overview of anticoagulant intervention trials in COVID-19 categorized on disease stage, adapted from.¹ DOAC: Direct Oral Anticoagulant; DTI: Direct Thrombin Inhibitors; ICU: Intensive Care Unit; X indicates that studies are still ongoing.

Ambulant Patients (Stage 1)									
HEPARIN Prophylactic dose	Study	N	results	DOAC Therapeutic dose	Study	N	results		
	ETHIC	1370	X		Apixaban	ACTIV-4b	7000	X	
	OVID	1000	X		Edoxaban	CONVINCE	420	X	
HEPARIN Intermediate dose					HERO-19	172	X		
				Rivaroxaban	COVID-PREVENT	400	X		
DOAC Prophylactic dose				OTHER					
	Apixaban	ACTIV-4b	3000		X	Sulodexide	SulES-COVID	243	2
	Rivaroxaban	PREVENT-HD	4000		X				
		NCT 4504032	600		X				
		NCT 4673214	62		X				

Hospitalized non-ICU patients (Stage 2)

HEPARIN	Study	N	results	DOAC	Study	N	results	
Prophylactic dose				Prophylactic dose				
HEPARIN Intermediate dose	COVID-19-HD	300	X	DOAC Therapeutic dose	Rivaroxaban	ACOVACT	500	X
	EMOS-COVID	300	X		XACT	150	X	
	X-COVID-19	2712	X					
	EUCTR 2020-00189-14	140	X		Apixaban	FREEDOM COVID	3600	X
	NCT 41360824	170	X		Rivaroxaban	ACTION	600	X
HEPARIN Therapeutic dose	ACTION	600	X	XACT	150	X		
	ACTIVE-4a	520	³					
	ATTACC	1036	³					
	BEMICOP	164	X					
	BEMI COVID-19	120	X					
	FREEDOM COVID	3600	X					
	RAPID COVID	462	X					
	COAG							
	REMAP-CAP	216	³					
	NCT 4485429	268	X					
	NCT 4508439	130	X					

ICU patients (Stage 3)			
HEPARIN	Study	N	results
Prophylactic dose			
HEPARIN Intermediate dose	CoV-Hep	90	X
	IMPROVE	100	X
	INSPIRATION	600	X
	REMAP-CAP	Planned	X
HEPARIN Therapeutic dose	ACTIV-4a	129	4
	ATTAC	35	4
	COVID-PACT	750	X
	HESA-COVID	20	X
	TACOVID	15	X
	REMAP CAP	959	4
DTI Bivalirudin	ANTI-CO	100	X

non-ICU + ICU patients (Stage 2+3)			
HEPARIN	Study	N	results
Prophylactic dose			
HEPARIN Intermediate dose	COVI-DOSE	602	X
	DAWn-Antico	210	X
HEPARIN Therapeutic dose	CORRIMMUNO- COAG	808	X
	COVID-HEP	200	X
	HEP-COVID	308	X
	HEPMAB	308	X
	HERO-19	172	X
	IMPACT	186	X
	NCT 4377997	300	X
	NCT 4584580	50	X
DTI Argatroban	IMPACT	186	X

Post-discharge

DOAC**Prophylactic**

dose	Study	N	results
Apixaban	ACTIV-4c	5320	X
Rivaroxaban	MICHELLE	320	X

References

1. Talasaz AH, Sadeghipour P, Kakavand H, et al. Antithrombotic therapy in COVID-19: systematic summary of ongoing or completed randomized trials. *medRxiv* 2021; published online Jan 6. <https://doi.org/10.1101/2021.01.04.21249227> (preprint).
2. Gonzalez Ochoa AJ, Raffetto J, Hernandez Ibarra AG, et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. *Thromb Haemost* 2021; published online March 7. <https://doi.org/10.1055/a-1414-5216>.
3. ATTACC, ACTIV-4a and REMAP-CAP. Results of Interim Analysis. Jan 28, 2021. https://static1.squarespace.com/static/5cde3c7d9a69340001d79ffe/t/6013892709de942b53f6e3da/1611893037749/mpRCT+interim+presentation_v21-slides+22+and+23+corrected.pdf (accessed March 26, 2021).
4. The REMAP-CAP, ACTIV-4a, ATTACC Investigators, Zarychanski R. Therapeutic anticoagulation in critically ill patients with COVID-19 – preliminary report. *medRxiv* 2021; published online March 12. <https://doi.org/10.1101/2021.03.10.21252749> (preprint).